AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Arch Biopartners Inc.

CAD 0.93 -$0.32 (-25.60%)
TSXV · 14 Sep 2026 19:59 UTC
Previous Close
CAD 0.92
Day Range
CAD 0.86CAD 0.93
Year Range
CAD 0.39CAD 1.66
Market Cap
63.18M
AVG Volume
62.59K
Trailing/Forward PE
-21.88/-
PEG ratio
0.29
Dividend Yield
-
Next Earnings Date
2027-02-02
Primary Exchange
Toronto Stock Exchange VenturesCA
Revenue (CAD) · TTM
-1M01M2M3M24 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Revenue (CAD) · TTM by quarter
PeriodRevenue (CAD) · TTM
26 Q30
26 Q20
26 Q10
25 Q40
25 Q3-361K
25 Q2-361K
25 Q11.82M
24 Q42.12M
24 Q31.38M
24 Q21.5M
Net Income (CAD) · TTM
-4M-3M-2M-1M024 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Net Income (CAD) · TTM by quarter
PeriodNet Income (CAD) · TTM
26 Q3-2.83M
26 Q2-2.59M
26 Q1-2.7M
25 Q4-1.55M
25 Q3-2.39M
25 Q2-3.03M
25 Q1-3.55M
24 Q4-3.92M
24 Q3-2.57M
24 Q2-2.14M
Operating Income (CAD) · TTM
-4M-3M-2M-1M024 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Operating Income (CAD) · TTM by quarter
PeriodOperating Income (CAD) · TTM
26 Q3-2.59M
26 Q2-2.43M
26 Q1-2.49M
25 Q4-1.37M
25 Q3-1.82M
25 Q2-2.41M
25 Q1-3.04M
24 Q4-3.47M
24 Q3-2.4M
24 Q2-2.11M
EBITDA (CAD) · TTM
-3M-2M-1M024 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V EBITDA (CAD) · TTM by quarter
PeriodEBITDA (CAD) · TTM
26 Q3-2.58M
26 Q2-2.33M
26 Q1-2.43M
25 Q4-1.29M
25 Q3-2.07M
25 Q2-1.93M
25 Q1-2.43M
24 Q4-2.78M
24 Q3-1.43M
24 Q2-1.74M
Cash Flows (CAD) · TTM
-3M-2M-1M01M24 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Cash Flows (CAD) · TTM by quarter
PeriodCash Flows (CAD) · TTM
26 Q3-1.72M
26 Q2-1.09M
26 Q1-1.53M
25 Q4-1.58M
25 Q3-1.8M
25 Q2-2.77M
25 Q1-2.7M
24 Q4-2.35M
24 Q3-2.73M
24 Q210.53K
EPS (CAD) · TTM
-0.08-0.06-0.04-0.02024 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V EPS (CAD) · TTM by quarter
PeriodEPS (CAD) · TTM
26 Q3-0.04
26 Q2-0.04
26 Q1-0.04
25 Q4-0.02
25 Q3-0.04
25 Q2-0.05
25 Q1-0.06
24 Q4-0.06
24 Q3-0.04
24 Q2-0.03
Expenses (CAD) · TTM
-2M02M4M6MR&DSG&ACapex24 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Expenses (CAD) · TTM by quarter
PeriodExpenses (CAD) · TTM
26 Q32.15M
26 Q22.09M
26 Q12.21M
25 Q41.14M
25 Q31.84M
25 Q22.25M
25 Q14.91M
24 Q45.51M
24 Q33.06M
24 Q22.88M
Shares Outstanding · TTM
-600K-400K-200K024 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q3
ARCH.V Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
26 Q30
26 Q20
26 Q10
25 Q40
25 Q30
25 Q20
25 Q10
24 Q4-579.99K
24 Q3-579.99K
24 Q2-579.99K
PE Ratio
2004006008001000med 417.53Apr 22May 22Jun 22Jun 22Jul 22Aug 22Sep 22
ARCH.V PE Ratio by quarter
PeriodPE Ratio
Sep 22212.54
Sep 22227.57
Sep 22229.71
Sep 22232.57
Aug 22241.88
Aug 22240.45
Aug 22246.89
Aug 22248.32
Jul 22251.9
Jul 22246.89
Jul 22248.32
Jul 22261.2
Jun 22214.68
Jun 22573.87
Jun 22598.46
Jun 22610.76
Jun 22604.61
May 22627.15
May 22641.5
May 22739.88
May 22809.56
Apr 22807.51
Apr 22821.86
Apr 22836.21
Apr 22840.3
Apr 22856.7
Free Cash Flow Yield
-6%-5%-4%-3%-2%-1%med -2.38%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
ARCH.V Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-1.75%
Sep 26-1.77%
Sep 26-1.6%
Aug 26-1.5%
Aug 26-1.46%
Aug 26-1.47%
Aug 26-1.54%
Jul 26-2.01%
Jul 26-1.87%
Jul 26-1.94%
Jul 26-1.9%
Jul 26-1.77%
Jun 26-2.44%
Jun 26-3.46%
Jun 26-4.54%
Jun 26-4.73%
May 26-5.2%
May 26-5.2%
May 26-5.39%
May 26-5.32%
May 26-5.32%
Apr 26-4.88%
Apr 26-5.03%
Apr 26-4.14%
Apr 26-3.86%
Mar 26-4.36%
Mar 26-4.2%
Mar 26-3.38%
Mar 26-3%
Feb 26-2.85%
Feb 26-2.6%
Feb 26-2.52%
Feb 26-3.07%
Jan 26-2.42%
Jan 26-1.9%
Jan 26-1.74%
Jan 26-1.82%
Jan 26-1.92%
Dec 25-2.19%
Dec 25-2.19%
Dec 25-2.14%
Dec 25-2.17%
Nov 25-2.64%
Nov 25-2.59%
Nov 25-2.59%
Nov 25-2.56%
Oct 25-2.74%
Oct 25-2.77%
Oct 25-2.77%
Oct 25-2.47%
Oct 25-2.3%
Sep 25-3.02%
Sep 25-2.54%
Sep 25-2.56%
Sep 25-2.56%
Aug 25-2.51%
Aug 25-2.56%
Aug 25-2.51%
Aug 25-2.43%
Aug 25-2.41%
Jul 25-2.58%
Jul 25-2.44%
Jul 25-2.46%
Jul 25-2.41%
Jun 25-2.21%
Jun 25-2.39%
Jun 25-2.24%
Jun 25-2.24%
May 25-2.34%
May 25-2.38%
May 25-2.43%
May 25-2.42%
May 25-2.41%
Apr 25-2.38%
Apr 25-2.31%
Apr 25-2.2%
Apr 25-2.46%
Mar 25-2.07%
Mar 25-1.96%
Mar 25-1.94%
Mar 25-2.04%
Feb 25-1.94%
Feb 25-1.91%
Feb 25-1.93%
Feb 25-1.92%
Jan 25-1.98%
Jan 25-1.89%
Jan 25-1.93%
Jan 25-1.86%
Jan 25-1.81%
Dec 24-2.38%
Dec 24-2.46%
Dec 24-2.33%
Dec 24-2.23%
Nov 24-2.23%
Nov 24-2.23%
Nov 24-2.17%
Nov 24-2.12%
Nov 24-2.23%
Oct 24-2.18%
Price to Sales
-400-2000200med 58.86Apr 24Jul 24Nov 24Feb 25May 25Sep 25Dec 25
ARCH.V Price to Sales by quarter
PeriodPrice to Sales
Dec 25-227.07
Dec 25-227.07
Dec 25-232.56
Dec 25-228.9
Nov 25-188.61
Nov 25-192.28
Nov 25-192.28
Nov 25-194.11
Oct 25-181.29
Oct 25-179.46
Oct 25-179.46
Oct 25-201.43
Oct 25-216.08
Sep 25-253.89
Sep 25-301.04
Sep 25-299.23
Sep 25-299.23
Aug 25-304.67
Aug 25-299.23
Aug 25-304.67
Aug 25-315.55
Aug 25-317.37
Jul 25-297.42
Jul 25-313.74
Jul 25-311.93
Jul 25-317.37
Jun 2566.97
Jun 2561.98
Jun 2566.26
Jun 2566.26
May 2563.41
May 2562.34
May 2560.92
May 2561.27
May 2561.63
Apr 2562.34
Apr 2564.12
Apr 2567.33
Apr 2560.2
Mar 2553.34
Mar 2556.39
Mar 2557
Mar 2554.25
Feb 2557
Feb 2557.91
Feb 2557.3
Feb 2557.61
Jan 2555.78
Jan 2558.52
Jan 2557.3
Jan 2559.43
Jan 2560.96
Dec 2483.03
Dec 2480.31
Dec 2484.85
Dec 2488.48
Nov 2488.48
Nov 2488.48
Nov 2491.2
Nov 2493.01
Nov 2488.48
Oct 2490.74
Oct 2497.1
Oct 2484.85
Oct 2484.39
Sep 2475.75
Sep 2468.64
Sep 2465.71
Sep 2462.78
Aug 2460.68
Aug 2459.43
Aug 2462.36
Aug 2462.78
Aug 2464.87
Jul 2466.54
Jul 2465.71
Jul 2467.8
Jul 2470.31
Jun 2456.83
Jun 2455.82
Jun 2457.17
Jun 2459.2
May 2456.49
May 2457.17
May 2457.51
May 2457.85
May 2459.88
Apr 2464.28
Apr 2480.51
Apr 2480.17
Apr 2480.17
Mar 2470.71
Mar 2477.34
Mar 2469.45
Mar 2455.24
Mar 2447.98
Feb 2447.98
Feb 2444.82
Feb 2445.14
Feb 2444.19
EV/EBITDA
0200040006000med 371.54Apr 22May 22Jul 22Aug 22Sep 22Nov 22Dec 22
ARCH.V EV/EBITDA by quarter
PeriodEV/EBITDA
Dec 223574.52
Dec 223793.02
Dec 223831.58
Dec 223780.17
Nov 223805.87
Nov 223934.4
Nov 224101.49
Nov 224191.46
Oct 224255.73
Oct 224242.87
Oct 223831.58
Oct 223831.58
Sep 223947.26
Sep 22156.52
Sep 22167.37
Sep 22168.92
Sep 22170.99
Aug 22177.71
Aug 22176.67
Aug 22181.33
Aug 22182.36
Jul 22184.94
Jul 22181.33
Jul 22182.36
Jul 22191.66
Jun 22158.07
Jun 22289.52
Jun 22301.67
Jun 22307.75
Jun 22304.71
May 22315.85
May 22322.94
May 22371.54
May 22405.97
Apr 22404.96
Apr 22412.04
Apr 22419.13
Apr 22421.16
Apr 22429.26
Price/Operating Cashflow
050001000015000med 578.81Apr 22May 22Jul 22Aug 22Jul 24Aug 24Sep 24
ARCH.V Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2410786.09
Sep 249773.04
Sep 249355.89
Sep 248938.75
Aug 248640.79
Aug 248462.02
Aug 248879.16
Aug 248938.75
Aug 249236.71
Jul 249475.08
Jul 249355.89
Jul 249653.85
Jul 2410011.4
Sep 22180.71
Sep 22193.49
Sep 22195.32
Sep 22197.75
Aug 22205.66
Aug 22204.45
Aug 22209.92
Aug 22211.14
Jul 22214.18
Jul 22209.92
Jul 22211.14
Jul 22222.09
Jun 22182.54
Jun 22448.94
Jun 22468.18
Jun 22477.8
Jun 22472.99
May 22490.62
May 22501.85
May 22578.81
May 22633.32
Apr 22631.72
Apr 22642.94
Apr 22654.16
Apr 22657.37
Apr 22670.2
Price to Book
55006000650070007500med 6616.64Apr 16Apr 16Apr 16May 16May 16Jun 16Jun 16
ARCH.V Price to Book by quarter
PeriodPrice to Book
Jun 165671.41
Jun 166549.12
Jun 166886.71
Jun 166751.67
May 167021.74
May 166751.67
May 166616.64
May 166616.64
Apr 166211.54
Apr 166279.06
Apr 166616.64
Apr 166481.61
Apr 166751.67
Arch Biopartners Inc.
ARCH.V
Stockpicker

Video analysis: ARCH.V

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.